Business Description
Guardant Health Inc
NAICS : 621511
SIC : 8071
ISIN : US40131M1099
Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.86 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 8.53 | |||||
| Debt-to-EBITDA | -3.12 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.7 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | -18.8 | |||||
| 3-Year EPS without NRI Growth Rate | -18.1 | |||||
| 3-Year FCF Growth Rate | -24 | |||||
| 3-Year Book Growth Rate | -53.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 27.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 24.27 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 95.71 | |||||
| 9-Day RSI | 63.99 | |||||
| 14-Day RSI | 31.97 | |||||
| 6-1 Month Momentum % | -37.58 | |||||
| 12-1 Month Momentum % | -48.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.54 | |||||
| Quick Ratio | 6.24 | |||||
| Cash Ratio | 5.68 | |||||
| Days Inventory | 95.68 | |||||
| Days Sales Outstanding | 58.06 | |||||
| Days Payable | 111.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 | |||||
| Shareholder Yield % | 0.67 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.74 | |||||
| Operating Margin % | -100.14 | |||||
| Net Margin % | -85.02 | |||||
| FCF Margin % | -61.29 | |||||
| ROE % | -344.76 | |||||
| ROA % | -28.05 | |||||
| ROIC % | -105.86 | |||||
| ROC (Joel Greenblatt) % | -147.12 | |||||
| ROCE % | -31.69 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.44 | |||||
| PB Ratio | 13.29 | |||||
| Price-to-Tangible-Book | 14.45 | |||||
| EV-to-EBIT | -4.82 | |||||
| EV-to-Forward-EBIT | -5.11 | |||||
| EV-to-EBITDA | -5.3 | |||||
| EV-to-Forward-EBITDA | -6.71 | |||||
| EV-to-Revenue | 4.07 | |||||
| EV-to-Forward-Revenue | 3.46 | |||||
| EV-to-FCF | -6.65 | |||||
| Earnings Yield (Greenblatt) % | -20.75 | |||||
| FCF Yield % | -16.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guardant Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 9,872.683 | ||
| EPS (TTM) (MXN) | -75.255 | ||
| Beta | 1.65 | ||
| Volatility % | 60.98 | ||
| 14-Day RSI | 31.97 | ||
| 14-Day ATR (MXN) | 1.48758 | ||
| 20-Day SMA (MXN) | 294.547 | ||
| 12-1 Month Momentum % | -48.52 | ||
| 52-Week Range (MXN) | 293.83 - 662.5 | ||
| Shares Outstanding (Mil) | 121.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guardant Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guardant Health Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guardant Health Inc Frequently Asked Questions
What is Guardant Health Inc(MEX:GH)'s stock price today?
The current price of MEX:GH is MXN301.00. The 52 week high of MEX:GH is MXN662.50 and 52 week low is MXN293.83.
When is next earnings date of Guardant Health Inc(MEX:GH)?
The next earnings date of Guardant Health Inc(MEX:GH) is 2024-05-09.
Does Guardant Health Inc(MEX:GH) pay dividends? If so, how much?
Guardant Health Inc(MEX:GH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers